These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33694082)

  • 21. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.
    Zumla A; Memish ZA; Maeurer M; Bates M; Mwaba P; Al-Tawfiq JA; Denning DW; Hayden FG; Hui DS
    Lancet Infect Dis; 2014 Nov; 14(11):1136-1149. PubMed ID: 25189352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections.
    Rahman Sabuj MZ; Islam N
    Nanoscale Adv; 2021 Jul; 3(14):4005-4018. PubMed ID: 36132845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticle approaches against bacterial infections.
    Gao W; Thamphiwatana S; Angsantikul P; Zhang L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(6):532-47. PubMed ID: 25044325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhalable nanoparticulate powders for respiratory delivery.
    Muralidharan P; Malapit M; Mallory E; Hayes D; Mansour HM
    Nanomedicine; 2015 Jul; 11(5):1189-99. PubMed ID: 25659645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.
    Li J; Zheng H; Leung SSY
    Pharm Res; 2023 May; 40(5):1057-1072. PubMed ID: 36123511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary biofilm-based chronic infections and inhaled treatment strategies.
    Ding L; Wang J; Cai S; Smyth H; Cui Z
    Int J Pharm; 2021 Jul; 604():120768. PubMed ID: 34089796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary drug delivery systems for antimicrobial agents: facts and myths.
    Falagas ME; Michalopoulos A; Metaxas EI
    Int J Antimicrob Agents; 2010 Feb; 35(2):101-6. PubMed ID: 19939637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
    Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B
    Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled antimicrobial therapy - barriers to effective treatment.
    Weers J
    Adv Drug Deliv Rev; 2015 May; 85():24-43. PubMed ID: 25193067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current advances in drug delivery of nanoparticles for respiratory disease treatment.
    de Menezes BRC; Rodrigues KF; Schatkoski VM; Pereira RM; Ribas RG; Montanheiro TLDA; Thim GP
    J Mater Chem B; 2021 Feb; 9(7):1745-1761. PubMed ID: 33508058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for lower respiratory tract infections.
    Liapikou A; Torres A
    Expert Opin Pharmacother; 2014 Nov; 15(16):2307-18. PubMed ID: 25216725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children.
    Jacobs MR
    Pediatr Infect Dis J; 2003 Aug; 22(8 Suppl):S109-19. PubMed ID: 14566997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.
    Lim YH; Tiemann KM; Hunstad DA; Elsabahy M; Wooley KL
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Nov; 8(6):842-871. PubMed ID: 27016134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local drug delivery in the urinary tract: current challenges and opportunities.
    Mittal R; Pan DR; Parrish JM; Huang EH; Yang Y; Patel AP; Malhotra AK; Mittal J; Chhibber S; Harjai K
    J Drug Target; 2018 Sep; 26(8):658-669. PubMed ID: 29251520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K; Chono S; Morimoto K
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Are new antibiotics in therapy of respiratory tract infections necessary?].
    Haberl R; Wenisch C; Domej W
    Wien Med Wochenschr; 2003; 153(15-16):345-8. PubMed ID: 13677256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape.
    Alabresm A; Chandler SL; Benicewicz BC; Decho AW
    Bioconjug Chem; 2021 Aug; 32(8):1411-1430. PubMed ID: 34319073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoantibiotics: A Novel Rational Approach to Antibiotic Resistant Infections.
    Engin AB; Engin A
    Curr Drug Metab; 2019; 20(9):720-741. PubMed ID: 31385767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.